A platelet-activating factor antagonist inhibits interleukin 1-induced inflammation

Area of Science:

• Ophthalmology
• Immunology
• Pharmacology

Background:

• Interleukin 1 (IL-1) plays a key role in ocular inflammation.
• Vascular permeability and leukocyte infiltration are hallmarks of IL-1-induced ocular inflammation.
• The roles of platelet-activating factor (PAF) and prostaglandins in IL-1-mediated ocular inflammation require further elucidation.

Purpose of the Study:

• To investigate the role of platelet-activating factor (PAF) in interleukin 1-alpha (IL-1α)-induced ocular inflammation in rabbits.
• To determine if PAF acts independently or synergistically with prostaglandins in mediating IL-1α-induced vascular permeability and leukocyte infiltration.
• To evaluate the therapeutic potential of a PAF receptor antagonist in combination with prostaglandin synthesis inhibitors.

Main Methods:

• Intravitreal injection of human IL-1α into rabbit eyes.
• Administration of a PAF receptor antagonist (SRI 63-441), a prostaglandin-synthetase inhibitor (flurbiprofen), or a corticosteroid (prednisolone).
• Measurement of vascular permeability and leukocyte infiltration.
• Quantification of prostaglandin E2 (PGE2) levels.

Main Results:

• SRI 63-441 significantly inhibited IL-1α-induced vascular permeability and leukocyte infiltration.
• Flurbiprofen and prednisolone also attenuated vascular permeability but did not affect IL-1α-induced PGE2 levels.
• SRI 63-441 did not reduce IL-1α-induced PGE2 levels, unlike flurbiprofen.
• Combined treatment with SRI 63-441 and flurbiprofen nearly abolished IL-1α-induced vascular permeability and cellular infiltration.

Conclusions:

• Platelet-activating factor (PAF) is implicated as a mediator in IL-1-induced ocular inflammation.
• PAF and prostaglandins appear to act synergistically to mediate IL-1-induced vascular permeability.
• Combined blockade of PAF and prostaglandin synthesis offers a promising therapeutic strategy for IL-1-mediated ocular inflammatory conditions.